```markdown
---
application_number: 214522Orig1s000
application_type: Original Application
letter_type: Other Action Letter
center: Center for Drug Evaluation and Research
division: Division of Cardiology and Nephrology
office: Office of Cardiology, Hematology, Endocrinology, and Nephrology
signatory_name: Norman Stockbridge, MD, PhD
signatory_title: Director
date_signed: 2021-02-23T12:20:36-05:00
reference_id: 4751240
contact:
  name: Christine (Tina) Sadr
  title: Regulatory Health Project Manager
  phone: 240-402-6554
---

## Critical Data

- **Application Number:** 214522Orig1s000  
- **Application Type:** Original Application  
- **Letter Type:** Other Action Letter  
- **Center:** Center for Drug Evaluation and Research  
- **Division:** Division of Cardiology and Nephrology  
- **Office:** Office of Cardiology, Hematology, Endocrinology, and Nephrology  
- **Signatory:** Norman Stockbridge, MD, PhD, Director  
- **Date Signed:** February 23, 2021  
- **Reference ID:** 4751240  
- **Contact Person:** Christine (Tina) Sadr  
- **Contact Title:** Regulatory Health Project Manager  
- **Contact Phone:** 240-402-6554  

---

# Center for Drug Evaluation and Research

**Application Number:** 214522Orig1s000  
**Other Action Letters**

---

## OTHER

Within one year after the date of this letter, you are required to resubmit or take other actions available under 21 CFR 314.110. If you do not take one of these actions, we may consider your lack of response a request to withdraw the application under 21 CFR 314.65. You may also request an extension of time in which to resubmit the application.

A resubmission must fully address all the deficiencies listed in this letter and should be clearly marked with **"RESUBMISSION"** in large font, bolded type at the beginning of the cover letter of the submission. The cover letter should clearly state that you consider this resubmission a complete response to the deficiencies outlined in this letter. A partial response to this letter will not be processed as a resubmission and will not start a new review cycle.

You may request a meeting or teleconference with us to discuss what steps you need to take before the application may be approved. If you wish to have such a meeting, submit your meeting request as described in the draft guidance for industry _Formal Meetings Between the FDA and Sponsors or Applicants of PDUFA Products_.

The drug product may not be legally marketed until you have been notified in writing that this application is approved.

If you have any questions, contact Christine (Tina) Sadr, Regulatory Health Project Manager, at 240-402-6554.

Sincerely,  
**Norman Stockbridge, MD, PhD**  
Director  
Division of Cardiology and Nephrology  
Office of Cardiology, Hematology, Endocrinology, and Nephrology  
Center for Drug Evaluation and Research  

---

This is a representation of an electronic record that was signed electronically. Following this are manifestations of any and all electronic signatures for this electronic record.

---

**/s/**  
**NORMAN L STOCKBRIDGE**  
02/23/2021 12:20:36 PM  
Signature Page 1 of 1  
Reference ID: 4751240
```